---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-015851"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2025-02-07T23:59:59+00:00"
generated_at: "2026-05-27T00:56:39.402147+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics Q4 net loss $6.6M; cash $24.1M, ORLYNVAH approved

## Summary
- Net loss Q4 2024 $6.6M vs $12.4M in Q4 2023; full year $24.8M vs $38.4M.
- Cash and equivalents $24.1M at Dec 31, 2024; including $4.8M ATM proceeds Jan-Feb 2025, runway into H2 2025.
- R&D expenses fell to $1.3M in Q4 2024 from $9.7M, driven by lower REASSURE trial costs.
- ORLYNVAH (sulopenem etzadroxil/probenecid) approved by FDA for uUTIs in Q4 2024; pre-commercialization underway.
- Repaid outstanding 6.500% Exchangeable Notes due 2025 in January 2025.

## SEC filing metadata
- accession: 0000950170-25-015851
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2025-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015851/0000950170-25-015851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015851/itrm-20250207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-015851
- JSON: https://secwatch.observer/filing/0000950170-25-015851.json
- Plain text: https://secwatch.observer/filing/0000950170-25-015851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.